Kanishka Sircar, M.D.

Peer-Reviewed Articles

1. Tang, C, Seo, A, Sherry, AD, Yang, P, Kobayashi, K, Sircar, K, Genovese, G, Jonasch, E, Shah, AY, Zurita-Saavedra, A, Kovitz, CA, Campbell, M, Su, S, Yang, J, Ratzel, S, Acevedo, A, LaBella, ML, Battey, CJ, Steiner, C, Ascione, L, Liu, X, Hannan, R, Shapiro, DD, Choueiri, TK, Tannir, NM, Msaouel, P, Xu, W. KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma. European urology 89(4):313-317, 2026. e-Pub 2026. PMID: 41765697.
2. Msaouel, P, Yu, K, Yuan, Y, Chen, J, Yan, X, Karki, M, Duan, F, Sheth, RA, Rao, P, Sircar, K, Shah, AY, Zurita-Saavedra, A, Genovese, G, Li, M, Yeh, CC, Dang, M, Han, G, Chu, Y, Hallin, M, Olson, P, Yang, R, Slavin, D, Der-Torossian, H, Chin, CD, Tannir, NM, Wang, L, Gao, J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 39794332.
3. Ruiz-Cordero R, Wang Q, Kumar G, Akgul M, Creighton CJ, Rao P, Tamboli P, Zheng L, Zhao J, Murugan P, Shen S, Brimo F, Ezhilarasan R, Sulman E, Wani K, Lazar AJ, Kim T, Chen K, Bhat KPL, Kannan K, Wang J, Karam JA, Sircar K. Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples. Eur Urol Oncol 8(6):1629-1638, 2025. e-Pub 2025. PMID: 41193273.
4. Tang C, Sherry AD, Seo A, Hara K, Choi H, Liu S, Sun X, Montoya A, Ludmir EB, Shah AY, Jonasch E, Zurita AJ, Kovitz C, Alhalabi O, Goswami S, Hahn AW, Campbell MT, Hernandez A, Nead KT, Van Loo P, Su S, Battey CJ, LaBella ML, Ratzel S, Acevedo A, Genovese G, Sircar K, Karam JA, Tannir NM, Msaouel P. Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. Lancet Oncol 26(10):1289-1299, 2025. e-Pub 2025. PMID: 40915303.
5. Gilligan, TD, Lin, DW, Adra, N, Bagrodia, A, Feldman, DR, Yamoah, K, Aggarwal, R, Chandrasekar, T, Costa, D, Drakaki, A, Eggener, SE, Emamekhoo, H, Geynisman, DM, Graham, LS, Humphrey, P, Leuva, H, Levine, EG, Luckenbaugh, AN, Maughan, B, McGregor, BA, Monk, P, Picus, J, Pierorazio, P, Rais-Bahrami, S, Reichert, ZR, Rwigema, JM, Saylor, P, Shah, A, Shah, SA, Singla, N, Sircar, K, VanderWeele, D, Zhumkhawala, A, Montgomery, S, Sliker, B. Testicular Cancer, Version 2.2025 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network 23(4), 2025. e-Pub 2025. PMID: 40203876.
6. Moussa, MJ, Khandelwal, J, Wilson, NR, Malikayil, KL, Surasi, DS, Bathala, TK, Lin, Y, Rao, P, Tamboli, P, Sircar, K, Ajufo, HO, Elsayes, KM, Shah, AY, Johns, AC, Goswami, S, Hasanov, E, Jonasch, E, Msaouel, P, Campbell, M, Alhalabi, O, Tannir, NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. Journal for immunotherapy of cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
7. Bhat, P, Tamboli, P, Sircar, K, Kannan, KS. Spatial Distribution of Tumor Cells in Clear Cell Renal Cell Carcinoma Is Associated with Metastasis and a Matrisome Gene Expression Signature. Cancers 17(2), 2025. e-Pub 2025. PMID: 39858031.
8. Serrano AG, Rocha P, Lima CF, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like Ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8(1):268, 2024. e-Pub 2024. PMID: 39558076.
9. Hwang MJ, Brennan PM, Monge BM, Alkamachi B, Rohra P, Peshoff MM, Sharma P, Sircar K, Tamboli P, Rao P. Best practices and recommendations for grossing and reporting of post-immunotherapy nephrectomy specimens. Diagn Histopathol 30(5):275-281, 2024. e-Pub 2024.
10. Hahn AW, Surasai D, Vicuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Johasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2024. PMID: 38035767.
11. Perelli, L, Carbone, F, Zhang, L, Huang, JK, Le, C, Khan, H, Citron, F, Del Poggetto, E, Gutschner, T, Tomihara, H, Soeung, M, Minelli, R, Srinivasan, S, Peoples, M, Lam, TA, Lundgren, S, Xia, R, Zhu, C, Mohamed, AM, Zhang, J, Sircar, K, Sgambato, A, Gao, J, Jonasch, E, Draetta, G, Futreal, A, Bakouny, Z, Van Allen, EM, Choueiri, TK, Signoretti, S, Msaouel, P, Litchfield, K, Turajlic, S, Wang, L, Chen, YB, Di Natale, RG, Hakimi, AA, Giuliani, V, Heffernan, TP, Viale, A, Bristow, C, Tannir, NM, Carugo, A, Genovese, G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nature Cancer 4(7):984-1000, 2023. e-Pub 2023. PMID: 37365326.
12. Alhalabi, O, Thouvenin, J, Negrier, S, Vano, Y, Campedel, L, Hasanov, E, Bakouny, Z, Hahn, AW, Bilen, MA, Msaouel, P, Choueiri, TK, Viswanathan, SR, Sircar, K, Albiges, L, Malouf, GG, Tannir, NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
13. Falahkheirkhah, K, Guo, T, Hwang, M, Tamboli, P, Wood, CG, Karam, JA, Sircar, K, Bhargava, R. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Laboratory Investigation 102(5):554-559, 2022. e-Pub 2022. PMID: 34963688.
14. Msaouel, P, Goswami, S, Thall, PF, Wang, X, Yuan, Y, Jonasch, E, Gao, J, Campbell, M, Shah, AY, Corn, P, Tam, AL, Ahrar, K, Rao, P, Sircar, K, Cohen, L, Basu, S, Duan, F, Jindal, S, Zhang, Y, Chen, H, Yadav, SS, Shazer, R, Der-Torossian, H, Allison, JP, Sharma, P, Tannir, NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science translational medicine 14(641), 2022. e-Pub 2022. PMID: 35442707.
15. Hahn, AW, Lebenthal, J, Genovese, G, Sircar, K, Tannir, NM, Msaouel, P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treatment and Research Communications 33, 2022. e-Pub 2022. PMID: 36174377.
16. Tang, C, Msaouel, P, Hara, K, Choi, H, Le, V, Shah, AY, Wang, J, Jonasch, E, Choi, S, Nguyen, Q, Das, P, Prajapati, S, Yu, Z, Khan, K, Powell, SF, Murthy, R, Sircar, K, Tannir, NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma. Lancet Oncology 22(12):1732-1739, 2021. e-Pub 2021. PMID: 34717797.
17. Wilson, NR, Wiele, AJ, Surasi, DS, Rao, P, Sircar, K, Tamboli, P, Shah, AY, Genovese, G, Karam, JA, Wood, CG, Tannir, NM, Msaouel, P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clinical Genitourinary Cancer 19(6):e401-e408, 2021. e-Pub 2021. PMID: 34625389.
18. Pieretti, AC, Westerman, ME, Childs, A, Millward, NZ, Shapiro, DD, Sircar, K, Rao, P, Jonasch, E, Campbell, M, Tannir, NM, Matin, S, Wood, CG, Karam, JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
19. Wiele, AJ, Surasi, DS, Rao, P, Sircar, K, Su, X, Bathala, TK, Shah, AY, Jonasch, E, Cataldo, VD, Genovese, G, Karam, JA, Wood, CG, Tannir, NM, Msaouel, P. Efficacy and safety of bevacizumab plus erlotinib in patients with renal medullary carcinoma. Cancers 13(9), 2021. e-Pub 2021. PMID: 33946504.
20. Chahoud, J, Msaouel, P, Ross, JA, McCormick, B, Bathala, TK, Gao, J, Horn, R, Xiao, L, Sircar, K, Campbell, M, Shah, AY, Goswami, S, Zurita-Saavedra, A, Jonasch, E, Matin, S, Wood, CG, Karam, JA, Sharma, P, Tannir, NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
21. Shaw, LK, Wiele, AJ, Sircar, K, Wood, CG, Msaouel, P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treatment Communications 27, 2021. e-Pub 2021. PMID: 33725559.
22. Cowman, SJ, Fuja, D, Liu, X, Tidwell, R, Kandula, N, Sirohi, D, Agarwal, AM, Emerson, L, Tripp, SR, Mohlman, JS, Stonhill, M, Garcia, G, Conley, CJ, Olalde, AA, Sargis, T, Ramirez-Torres, A, Karam, JA, Wood, CG, Sircar, K, Tamboli, P, Boucher, K, Maughan, B, Spike, BT, Ho, TH, Agarwal, N, Jonasch, E, Koh, MY. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research 26(18):4970-4982, 2020. e-Pub 2020. PMID: 32586940.
23. Ruiz-Cordero, R, Rao, P, Li, L, Qi, Y, Atherton, D, Peng, B, Singh, RR, Kim, T, Kawakami, F, Routbort, MJ, Alouch, N, Chow, CW, Tang, X, Lu, W, Brimo, F, Matin, S, Wood, CG, Tannir, NM, Wistuba, II, Chen, K, Wang, J, Medeiros, LJ, Karam, JA, Tamboli, P, Sircar, K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Modern Pathology 32(11):1698-1707, 2019. e-Pub 2019. PMID: 31231128.
24. Wang, F, Zhang, S, Kim, T, Lin, Yy, Iqbal, R, Wang, Z, Mohanty, V, Sircar, K, Karam, JA, Wendl, MC, Meric-Bernstam, F, Weinstein, JN, Ding, L, Mills, GB, Chen, K. Integrated transcriptomic–genomic tool Texomer profiles cancer tissues. Nature Methods 16(5):401-404, 2019. e-Pub 2019. PMID: 30988467.
25. Gilligan, TD, Lin, DW, Aggarwal, R, Chism, D, Cost, NG, Derweesh, IH, Emamekhoo, H, Feldman, DR, Geynisman, DM, Hancock, SL, Lagrange, C, Levine, EG, Longo, T, Lowrance, W, McGregor, BA, Monk, P, Picus, J, Pierorazio, P, Rais-Bahrami, S, Saylor, P, Sircar, K, Smith, DC, Tzou, K, Vaena, D, Vaughn, DJ, Yamoah, K, Yamzon, J, Johnson-Chilla, A, Keller, J, Pluchino, L. Testicular cancer, version 2.2020. JNCCN Journal of the National Comprehensive Cancer Network 17(12):1529-1554, 2019. e-Pub 2019. PMID: 31805523.
26. Sekino, Y, Sakamoto, N, Goto, K, Honma, R, Shigematsu, Y, Quoc, TP, Sentani, K, Oue, N, Teishima, J, Kawakami, F, Karam, JA, Sircar, K, Matsubara, A, Yasui, W. Uc.416 + A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC cancer 18(1), 2018. e-Pub 2018. PMID: 30286729.
27. Romero Arenas, MA, Whitsett, TG, Aronova, A, Henderson, SA, LoBello, J, Habra, MA, Grubbs, EG, Lee, JE, Sircar, K, Zarnegar, R, Scognamiglio, T, Fahey, TJ, Perrier, ND, Demeure, MJ. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. Annals of surgical oncology 25(3):801-807, 2018. e-Pub 2018. PMID: 29218429.
28. Kawakami, F, Sircar, K, Rodriguez Canales, J, Fellman, B, Urbauer, D, Tamboli, P, Tannir, NM, Jonasch, E, Wistuba, II, Wood, CG, Karam, JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 123(24):4823-4831, 2017. e-Pub 2017. PMID: 28832979.
29. Shah, AY, Karam, JA, Malouf, GG, Rao, P, Lim, ZD, Jonasch, E, Xiao, L, Gao, J, Vaishampayan, U, Heng, DY, Plimack, ER, Guancial, E, Fung, C, Lowas, SR, Tamboli, P, Sircar, K, Matin, S, Rathmell, WK, Wood, CG, Tannir, NM. Management and outcomes of patients with renal medullary carcinoma. BJU International 120(6):782-792, 2017. e-Pub 2017. PMID: 27860149.
30. Wang, Z, Kim, T, Peng, B, Karam, JA, Creighton, CJ, Joon, A, Kawakami, F, Trevisan, P, Jonasch, E, Chow, CW, Rodriguez Canales, J, Tamboli, P, Tannir, NM, Wood, CG, Monzon, FA, Baggerly, KA, Varella-Garcia, M, Czerniak, BA, Wistuba, II, Mills, GB, Shaw, KM, Chen, K, Sircar, K. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clinical Cancer Research 23(21):6686-6696, 2017. e-Pub 2017. PMID: 28710314.
31. Keskin, SK, Msaouel, P, Hess, KR, Yu, KJ, Matin, S, Sircar, K, Tamboli, P, Jonasch, E, Wood, CG, Karam, JA, Tannir, NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies. Journal of Urology 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
32. Kalra, S, Verma, J, Atkinson, BJ, Matin, S, Wood, CG, Karam, JA, Lin, S, Satcher, R, Tamboli, P, Sircar, K, Rao, P, Corn, P, Tannir, NM, Jonasch, E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer 15(3):363-370, 2017. e-Pub 2017. PMID: 28216278.
33. Wobker, SE, Przybycin, CG, Sircar, K, Epstein, J. Renal oncocytoma with vascular invasion. Human Pathology 58:1-6, 2016. e-Pub 2016. PMID: 27498062.
34. Thomas, AZ, Adibi, M, Tidwell, R, Borregales, LD, Merril, MM, Tamboli, P, Sircar, K, Jonasch, E, Tannir, NM, Matin, S, Wood, CG, Karam, JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology 196(3):678-684, 2016. e-Pub 2016. PMID: 27036304.
35. Malouf, GG, Ali, SM, Wang, K, Balasubramanian, S, Ross, JS, Miller, VA, Stephens, PJ, Khayat, D, Pal, S, Su, X, Sircar, K, Tamboli, P, Jonasch, E, Tannir, NM, Wood, CG, Karam, JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European urology 70(2):348-357, 2016. e-Pub 2016. PMID: 26895810.
36. Zheng, S, Cherniack, AD, Dewal, N, Moffitt, RA, Danilova, L, Murray, BA, Lerario, AM, Else, T, Knijnenburg, T, Ciriello, G, Kim, S, Assie, G, Morozova, O, Akbani, R, Shih, J, Hoadley, KA, Choueiri, TK, Waldmann, J, Mete, O, Gordon Robertson, A, Wu, HT, Raphael, BJ, Shao, L, Meyerson, M, Demeure, MJ, Beuschlein, F, Gill, AJ, Sidhu, SB, Almeida, MQ, Fragoso, MC, Cope, L, Kebebew, E, Habra, MA, Whitsett, TG, Bussey, KJ, Rainey, WE, Asa, SL, Bertherat, J, Fassnacht, M, Verhaak, R, Chin, L, Ju, Z, Kim, H, Ling, S, Liu, W, Lu, Y, Mills, GB, Sircar, K, Wang, Q, Weinstein, JN. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer cell 29(5):723-736, 2016. e-Pub 2016. PMID: 27165744.
37. Tannir, NM, Jonasch, E, Albiges, L, Altinmakas, E, Ng, CS, Matin, S, Wang, X, Qiao, W, Dubauskas Lim, Z, Tamboli, P, Rao, P, Sircar, K, Karam, JA, McDermott, DF, Wood, CG, Choueiri, TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European urology 69(5):866-874, 2016. e-Pub 2016. PMID: 26626617.
38. Kalra, S, Atkinson, BJ, Matrana, MR, Matin, S, Wood, CG, Karam, JA, Tamboli, P, Sircar, K, Rao, P, Corn, P, Tannir, NM, Jonasch, E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International 117(5):761-765, 2016. e-Pub 2016. PMID: 26032863.
39. Zhou, L, Liu, X, Sun, M, Zhang, X, German, P, Bai, S, Ding, Z, Tannir, NM, Wood, CG, Matin, S, Karam, JA, Tamboli, P, Sircar, K, Rao, P, Rankin, EB, Laird, DA, Hoang, A, Walker, CL, Giaccia, AJ, Jonasch, E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-2697, 2016. e-Pub 2016. PMID: 26364599.
40. Borregales, LD, Kim, DY, Staller, AL, Qiao, W, Thomas, AZ, Adibi, M, Tamboli, P, Sircar, K, Jonasch, E, Tannir, NM, Matin, S, Wood, CG, Karam, JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations 34(5):237.e19-237.e26, 2016. e-Pub 2016. PMID: 26707613.
41. Ozsari, L, Kutahyalioglu, M, Elsayes, KM, Vicens, RA, Sircar, K, Jazaerly, T, Waguespack, SG, Busaidy, NL, Cabanillas, ME, Dadu, R, Hu, MI, Vassilopoulou-Sellin, R, Jimenez, C, Lee, JE, Habra, MA. Preexisting adrenal masses in patients with adrenocortical carcinoma. Endocrine 51(2):351-359, 2016. e-Pub 2016. PMID: 26206754.
42. Sircar, K, Yoo, SY, Majewski, T, Wani, K, Patel, L, Voicu, H, Torres-Garcia, W, Verhaak, R, Tannir, NM, Karam, JA, Jonasch, E, Wood, CG, Tamboli, P, Baggerly, KA, Aldape, KD, Czerniak, BA. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. Journal of Pathology: Clinical Research 2(1):212-224, 2016. e-Pub 2016. PMID: 27499906.
43. Phan, L, Fuentes-Mattei, E, Wu, W, Velazquez-Torres, G, Sircar, K, Wood, CG, Hai, T, Jimenez, C, Cote, G, Ozsari, L, Hofmann, M, Zheng, S, Verhaak, R, Pagliaro, LC, Cortez, MA, Lee, M, Yeung, SJ, Habra, MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Research 75(19):4131-4142, 2015. e-Pub 2015. PMID: 26282167.
44. Adibi, M, Thomas, AZ, Borregales, LD, Merril, MM, Tidwell, R, Chen, HC, Sircar, K, Murugan, P, Tamboli, P, Jonasch, E, Tannir, NM, Matin, S, Wood, CG, Karam, JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations 33(10):427.e17-427.e23, 2015. e-Pub 2015. PMID: 26004164.
45. Singh, RR, Murugan, P, Patel, L, Voicu, H, Yoo, SY, Majewski, T, Mehrotra, M, Wani, K, Tannir, NM, Karam, JA, Jonasch, E, Wood, CG, Creighton, CJ, Medeiros, LJ, Broaddus, R, Tamboli, P, Baggerly, KA, Aldape, KD, Czerniak, BA, Luthra, R, Sircar, K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology 28(9):1225-1235, 2015. e-Pub 2015. PMID: 26111976.
46. Liu, X, Hoang, A, Zhou, L, Kalra, S, Yetil, A, Sun, M, Ding, Z, Zhang, X, Bai, S, German, P, Tamboli, P, Rao, P, Karam, JA, Wood, CG, Matin, S, Zurita-Saavedra, A, Bex, A, Griffioen, AW, Gao, J, Sharma, P, Tannir, NM, Sircar, K, Jonasch, E. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer Immunology Research 3(9):1017-1029, 2015. e-Pub 2015. PMID: 26014097.
47. Vodopivec, DM, Habra, MA, Ng, CS, Sircar, K, Grubbs, EG. Visual Vignette. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 21(7):854, 2015. e-Pub 2015. PMID: 26121444.
48. Merril, MM, Wood, CG, Tannir, NM, Tidwell, R, Babaian, KN, Jonasch, E, Pagliaro, LC, Compton, ZR, Tamboli, P, Sircar, K, Pisters, LL, Matin, S, Karam, JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations 33(4):166.e21-166.e29, 2015. e-Pub 2015. PMID: 25700975.
49. Shawa, H, Elsayes, KM, Javadi, S, Sircar, K, Jimenez, C, Habra, MA. Clinical and radiologic features of pheochromocytoma/ganglioneuroma composite tumors. Endocrine Practice 20(9):864-869, 2014. e-Pub 2014. PMID: 24641930.
50. Xu, B, Abourbih, S, Sircar, K, Kassouf, W, Aprikian, AG, Tanguay, S, Brimo, F. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma. Applied Immunohistochemistry and Molecular Morphology 22(3):206-212, 2014. e-Pub 2014. PMID: 23702650.
51. Ayala-Ramirez, M, Jasim, S, Feng, L, Ejaz, S, Deniz, F, Busaidy, NL, Waguespack, SG, Naing, A, Sircar, K, Wood, CG, Pagliaro, LC, Jimenez, C, Vassilopoulou-Sellin, R, Habra, MA. Adrenocortical carcinoma. European Journal of Endocrinology 169(6):891-899, 2013. e-Pub 2013. PMID: 24086089.
52. Abourbih, S, Sircar, K, Tanguay, S, Kassouf, W, Aprikian, AG, Mansure, J, Brimo, F. Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma. World journal of surgical oncology 11, 2013. e-Pub 2013. PMID: 24266898.
53. Xu, B, Abourbih, S, Sircar, K, Kassouf, W, Mansure, J, Aprikian, AG, Tanguay, S, Brimo, F. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma. Archives of Pathology and Laboratory Medicine 137(10):1326-1336, 2013. e-Pub 2013. PMID: 24079759.
54. Dayyani, F, Pettaway, CA, Kamat, A, Munsell, M, Sircar, K, Pagliaro, LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urologic Oncology: Seminars and Original Investigations 31(7):1171-1177, 2013. e-Pub 2013. PMID: 22534087.
55. Dayyani, F, Czerniak, BA, Sircar, K, Munsell, M, Millikan, RE, Dinney, CP, Siefker-Radtke, AO. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. Journal of Urology 189(5):1656-1661, 2013. e-Pub 2013. PMID: 23159581.
56. Choucair, KA, Guérard, KP, Ejdelman, J, Chevalier, S, Yoshimoto, M, Scarlata, E, Fazli, L, Sircar, K, Squire, JA, Brimo, F, Cunha, IW, Aprikian, AG, Gleave, ME, Lapointe, J. The 16p13.3 (PDPK1) genomic gain in prostate cancer. Translational Oncology 5(6):453-460, 2012. e-Pub 2012. PMID: 23401739.
57. Brimo, F, Sircar, K, Chevalier, S, Saad, F, Lacombe, L, Têtu, B, Scarlata, E, Aprikian, AG. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol. Cell and Tissue Banking 13(4):631-638, 2012. e-Pub 2012. PMID: 22200970.
58. Chuang, HH, Deniz, F, Sircar, K, Jimenez, C, De Celis, CR, Wood, CG, Habra, MA. [ 18F]fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma. Journal of Clinical Oncology 30(26):e246-e249, 2012. e-Pub 2012. PMID: 22649135.
59. Fritsche, HM, Novara, G, Burger, M, Gupta, A, Matsumoto, K, Kassouf, W, Sircar, K, Zattoni, F, Walton, TJ, Tritschler, S, Baba, S, Bastian, PJ, Martinez-Salamanca, JI, Seitz, C, Otto, W, Wieland, WF, Karakiewicz, PI, Ficarra, V, Hartmann, A, Shariat, SF. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 30(5):666-672, 2012. e-Pub 2012. PMID: 20933445.
60. Shariat, SF, Zigeuner, R, Rink, M, Margulis, V, Hansen, J, Kikuchi, E, Kassouf, W, Raman, JD, Remzi, M, Koppie, TM, Bensalah, K, Guo, CC, Mikami, S, Sircar, K, Ng, C, Haitel, A, Kabbani, W, Chun, FK, Wood, CG, Scherr, DS, Karakiewicz, PI, Langner, C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival. European urology 62(2):224-231, 2012. e-Pub 2012. PMID: 22285763.
61. Rink, M, Robinson, B, Green, DA, Cha, EK, Hansen, J, Comploj, E, Margulis, V, Raman, JD, Ng, C, Remzi, M, Bensalah, K, Kabbani, W, Haitel, A, Rioux-Leclercq, N, Guo, CC, Chun, FK, Kikuchi, E, Kassouf, W, Sircar, K, Sun, M, Sonpavde, G, Lotan, Y, Pycha, A, Karakiewicz, PI, Scherr, DS, Shariat, SF. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. Journal of Urology 188(2):398-404, 2012. e-Pub 2012. PMID: 22698626.
62. Sircar, K, Huang, H, Hu, L, Cogdell, D, Dhillon, J, Tzelepi, V, Efstathiou, E, Koumakpayi, IH, Saad, F, Luo, D, Bismar, TA, Aparicio, A, Troncoso, P, Navone, NM, Zhang, W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. American Journal of Pathology 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
63. Bismar, TA, Yoshimoto, M, Duan, Q, Liu, S, Sircar, K, Squire, JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 60(4):645-652, 2012. e-Pub 2012. PMID: 22260502.
64. Sircar, K, Huang, H, Hu, L, Liu, Y, Dhillon, J, Cogdell, D, Aprikian, AG, Efstathiou, E, Navone, NM, Troncoso, P, Zhang, W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PloS one 7(2), 2012. e-Pub 2012. PMID: 22363599.
65. Tzelepi, V, Zhang, J, Lu, JF, Kleb, B, Wu, G, Wan, X, Hoang, A, Efstathiou, E, Sircar, K, Navone, NM, Troncoso, P, Liang, S, Logothetis, CJ, Maity, S, Aparicio, A. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clinical Cancer Research 18(3):666-677, 2012. e-Pub 2012. PMID: 22156612.
66. Yoshimoto, M, Ludkovski, O, Degrace, D, Williams, JL, Evans, AJ, Sircar, K, Bismar, TA, Nuin, P, Squire, JA. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes and Cancer 51(2):149-160, 2012. e-Pub 2012. PMID: 22045666.
67. Zhang, HM, Perrier, ND, Grubbs, EG, Sircar, K, Ye, Z, Lee, JE, Ng, CS. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clinical Radiology 67(1):38-46, 2012. e-Pub 2012. PMID: 21783181.
68. Youssif, TA, Fahmy, MA, Koumakpayi, IH, Ayala, F, Al Marzooqi, S, Chen, G, Tamboli, P, Squire, JA, Tanguay, S, Sircar, K. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2):290-300, 2011. e-Pub 2011. PMID: 20830770.
69. Rickman, DS, Chen, YB, Banerjee, S, Pan, Y, Yu, J, Vuong, T, Perner, S, Lafargue, CJ, Mertz, KD, Setlur, SR, Sircar, K, Chinnaiyan, AM, Bismar, TA, Rubin, MA, Demichelis, F. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12(12):1031-1040, 2010. e-Pub 2010. PMID: 21170267.
70. Gorlov, IP, Sircar, K, Zhao, H, Maity, S, Navone, NM, Gorlova, OY, Troncoso, P, Pettaway, CA, Byun, J, Logothetis, CJ. Prioritizing genes associated with prostate cancer development. BMC cancer 10, 2010. e-Pub 2010. PMID: 21044312.
71. Zigeuner, R, Shariat, SF, Margulis, V, Karakiewicz, PI, Roscigno, M, Weizer, A, Kikuchi, E, Remzi, M, Raman, JD, Bolenz, C, Bensalah, K, Capitanio, U, Koppie, TM, Kassouf, W, Sircar, K, Patard, JJ, Fernandez, M, Wood, CG, Montorsi, F, Ströbel, P, Wheat, JC, Haitel, A, Oya, M, Guo, CC, Ng, C, Chade, DC, Sagalowsky, AI, Langner, C. Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European urology 57(4):575-581, 2010. e-Pub 2010. PMID: 19959276.
72. Al-Otaibi, MF, Youssif, TA, Alkhaldi, A, Sircar, K, Kassouf, W, Aprikian, AG, Mulder, D, Tanguay, S. Renal cell carcinoma with inferior vena caval extention. BJU International 104(10):1467-1470, 2009. e-Pub 2009. PMID: 19388993.
73. Sircar, K, Yoshimoto, M, Monzon, FA, Koumakpayi, IH, Katz, RL, Khanna, A, Alvarez, K, Chen, G, Darnel, AD, Aprikian, AG, Saad, F, Bismar, TA, Squire, JA. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. Journal of Pathology 218(4):505-513, 2009. e-Pub 2009. PMID: 19402094.
74. Aldousari, S, Sircar, K, Kassouf, W. Plasmacytoid urothelial carcinoma of the bladder. Cases Journal 2(4), 2009. e-Pub 2009.
75. Darnel, AD, Behmoaram, E, Vollmer, RT, Corcos, J, Bijian, K, Sircar, K, Su, J, Jiao, J, Alaoui-Jamali, MA, Bismar, TA. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clinical Cancer Research 15(4):1376-1383, 2009. e-Pub 2009. PMID: 19228738.
76. Szymanski, KM, Baazeem, A, Sircar, K, Tanguay, S, Kassouf, W. Primary renal carcinoid tumour with inferior vena caval tumour thrombus. Journal of the Canadian Urological Association 3(3):E7-E9, 2009. e-Pub 2009.
77. Al-Otaibi, MF, Ross, P, Fahmy, N, Jeyaganth, S, Trottier, H, Sircar, K, Bégin, L, Souhami, L, Kassouf, W, Aprikian, AG, Tanguay, S. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286-292, 2008. e-Pub 2008. PMID: 18484590.
78. Diallo, JS, Aldejmah, A, Mouhim, AF, Fahmy, MA, Koumakpayi, IH, Sircar, K, Bégin, L, Mes-Masson, AM, Saad, F. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens. BJU International 101(10):1302-1309, 2008. e-Pub 2008. PMID: 18294307.
79. Diallo, JS, Aldejmah, A, Mouhim, AF, Péant, B, Fahmy, MA, Koumakpayi, IH, Sircar, K, Bégin, L, Mes-Masson, AM, Saad, F. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clinical Cancer Research 13(23):7044-7052, 2007. e-Pub 2007. PMID: 18056181.
80. Sircar, K, Gottlieb, B, Alvarado, C, Aprikian, AG, Beitel, LK, Alam-Fahmy, M, Bégin, L, Trifiro, M. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer and Prostatic Diseases 10(4):360-368, 2007. e-Pub 2007. PMID: 17440439.
81. Mujoomdar, A, Maheshwari, S, Zand, KR, Sircar, K, Mesurolle, B. Sonographic diagnosis of a ruptured intratesticular pseudoaneurysm secondary to orchitis. American Journal of Roentgenology 189(1):136, 2007. e-Pub 2007. PMID: 17579129.
82. Binsaleh, S, Sircar, K, Elhilali, M, Anidjar, M. BCG for upper-tract transitional-cell carcinoma. Journal of Endourology 20(12):1068-1071, 2006. e-Pub 2006. PMID: 17206904.
83. Sircar, K, Gaboury, L, Ouadi, L, Mecteau, M, Scarlata, E, Saad, F, Aprikian, AG, Tanguay, S, Lapointe, S, Lussier, C, Miletti, T, Lanoix, J. Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens. Clinical Cancer Research 12(14 Pt 1):4178-4184, 2006. e-Pub 2006. PMID: 16857789.
84. Chen, G, Sircar, K, Aprikian, AG, Potti, A, Goltzman, D, Rabbani, SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2):289-298, 2006. e-Pub 2006. PMID: 16752412.
85. Alvarado, C, Beitel, LK, Sircar, K, Aprikian, AG, Trifiro, M, Gottlieb, B. Somatic mosaicism and cancer. Cancer Research 65(18):8514-8518, 2005. e-Pub 2005. PMID: 16166332.
86. Zakian, KL, Sircar, K, Hricak, H, Chen, HN, Shukla-Dave, A, Eberhardt, S, Muruganandham, M, Ebora, L, Kattan, MW, Reuter, V, Scardino, PT, Koutcher, JA. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3):804-814, 2005. e-Pub 2005. PMID: 15734935.
87. Chen, G, Shukeir, N, Potti, A, Sircar, K, Aprikian, AG, Goltzman, D, Rabbani, SA. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma. Cancer 101(6):1345-1356, 2004. e-Pub 2004. PMID: 15316903.
88. Binsaleh, S, Sircar, K, Chan, PT. Feasibility of simultaneous testicular microdissection for sperm retrieval and ipsilateral testicular tumor resection in azoospermic men. Journal of andrology 25(6):867-871, 2004. e-Pub 2004. PMID: 15477357.
89. Al-Assiri, M, Al-Otaibi, MF, Sircar, K, Laplante, M. Renal pelvis squamous cell carcinoma and renal cell carcinoma in a tuberculous kidney. TheScientificWorldJournal 4:965-968, 2004. e-Pub 2004. PMID: 15578119.
90. Zakian, KL, Eberhardt, S, Hricak, H, Shukla-Dave, A, Kleinman, S, Muruganandham, M, Sircar, K, Kattan, MW, Reuter, V, Scardino, PT, Koutcher, JA. Transition zone prostate cancer. Radiology 229(1):241-247, 2003. e-Pub 2003. PMID: 12920178.
91. Yossepowitch, O, Sircar, K, Scardino, PT, Ohori, M, Kattan, MW, Wheeler, TM, Reuter, V. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. Journal of Urology 168(5):2011-2015, 2002. e-Pub 2002. PMID: 12394697.
92. Huizinga, JD, Berezin, I, Sircar, K, Hewlett, BR, Donnelly, G, Bercik, P, Ross, C, Algoufi, T, Fitzgerald, P, Der, T, Riddell, R, Collins, SM, Jacobson, K. Development of interstitial cells of Cajal in a full-term infant without an enteric nervous system. Gastroenterology 120(2):561-567, 2001. e-Pub 2001. PMID: 11159897.
93. Robinson, TL, Sircar, K, Hewlett, BR, Chorneyko, K, Riddell, R, Huizinga, JD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. American Journal of Pathology 156(4):1157-1163, 2000. e-Pub 2000. PMID: 10751339.
94. Sircar, K, Hewlett, BR, Huizinga, JD, Chorneyko, K, Berezin, I, Riddell, R. Interstitial cells of cajal as precursors of gastrointestinal stromal tumors. American Journal of Surgical Pathology 23(4):377-389, 1999. e-Pub 1999. PMID: 10199467.

Review Articles

1. Hwang, MJ, Brennan, P, Monge, BM, Alkamachi, B, Rohra, P, Peshoff, MM, Sharma, P, Sircar, K, Tamboli, P, Rao, P. Best practices and recommendations for grossing and reporting of post-immunotherapy nephrectomy specimens. Diagnostic Histopathology 30(5):275-281, 2024. e-Pub 2024.
2. Subbiah, V, Sircar, K. Personalizing precision oncology. JNCCN Journal of the National Comprehensive Cancer Network 17(7):886-888, 2019. e-Pub 2019. PMID: 31319384.
3. Motzer, RJ, Jonasch, E, Agarwal, N, Beard, CJ, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Costello, BA, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Shuch, B, Sircar, K, Somer, B, Wilder, RB, Dwyer, M, Kumar, R. Testicular cancer, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network 13(6):772-799, 2015. e-Pub 2015. PMID: 26085393.
4. Motzer, RJ, Jonasch, E, Agarwal, N, Beard, CJ, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Costello, BA, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Shuch, B, Sircar, K, Somer, B, Wilder, RB, Dwyer, M, Kumar, R. Kidney cancer, version 3.2015. JNCCN Journal of the National Comprehensive Cancer Network 13(2):151-159, 2015. e-Pub 2015. PMID: 25691606.
5. Motzer, RJ, Jonasch, E, Agarwal, N, Beard, CJ, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Margolin, K, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Sircar, K, Somer, B, Wang, J, Wilder, RB, Dwyer, M, Kumar, R. Kidney cancer, version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network 12(2):175-182, 2014. e-Pub 2014. PMID: 24586079.
6. Sircar, K, Rao, P, Jonasch, E, Monzon, FA, Tamboli, P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chinese Journal of Cancer 32(6):303-311, 2013. e-Pub 2013. PMID: 23237216.
7. Pagliaro, LC, Tannir, NM, Sircar, K, Jonasch, E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert review of anticancer therapy 11(6):913-920, 2011. e-Pub 2011. PMID: 21707288.

Other Articles

1. Tang, C, Msaouel, P, Hara, K, Choi, H, Le, V, Shah, AY, Wang, J, Jonasch, E, Choi, S, Nguyen, Q, Das, P, Prajapati, S, Yu, ZH, Khan, K, Powell, SF, Murthy, R, Sircar, K, Tannir, NM Re. Journal of Urology 208(1):210, 2022. PMID: 35469446.
2. Cowman, SJ, Fuja, D, Liu, X, Tidwell, R, Kandula, N, Sirohi, D, Agarwal, AM, Emerson, L, Tripp, SR, Mohlman, JS, Stonhill, M, Garcia, G, Conley, CJ, Olalde, AA, Sargis, T, Ramirez-Torres, A, Karam, JA, Wood, CG, Sircar, K, Tamboli, P, Boucher, K, Maughan, B, Spike, BT, Ho, TH, Agarwal, N, Jonasch, E, Koh, MY Erratum. Clinical Cancer Research 27(11):3265, 2021. PMID: 34074655.
3. Hamdi, A, Mulanovich, VE, Matin, S, Landon, G, Sircar, K, Tu, S, Nieto, Y Isolated renal mucormycosis in a transplantation recipient. Journal of Clinical Oncology 33(10):e50-e51, 2015. PMID: 24821884.

Abstracts

1. Tang, C, Seo, A, Sherry, AD, Yang, P, Kobayashi, K, Sircar, K, Genovese, G, Jonasch, E, Shah, AY, Ratzel, S, Acevedo, A, Battey, CJ, Steiner, C, Ascione, L, Liu, X, Tannir, NM, Choueiri, TK, Msaouel, P, Xu, W. Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC) 44:537, 2026. e-Pub 2026.
2. Bernieh A, Stewart J, Wang Q, Wang J, Sircar K. Adult's Wilms Tumor: Twenty-Year Experience of a Tertiary Cancer Center with Clinicopathological and Molecular Annotation. United States and Canadian Academy of Pathologists 105(3), 2025. e-Pub 2025.
3. Zhang M, Vikram R, Sircar K, Troncoso P, Guo C, Tamboli P, Czerniak B. Primary Adenocarcinoma of the Urethra: A Clinicopathologic Study of 48 Cases. United States and Canadian Academy of Pathologists 105(3), 2025. e-Pub 2025.
4. Kumar G, Ruiz-Cordero R, Akgul M, Murugan P, Shen S, Brimo F, Rao P, Tamboli P, Crieghton C, Bhat K, Karam J, Kannan K, Sircar K. Gene Expression Signatures From FFPE Tumor Samples Can Predict For Clinically Indolent Renal Oncocytic Tumors. USCAP 113th Annual Meeting Bringing Education To LIfe 104(3):S982-83, 2024. e-Pub 2024.
5. Ebare K, Wang G, Wang Q, Nair V, Sathwik Iyer, Rao P, Tamboli P, Kannan K, Wang J, Karam J, Soleimani M, Bhat K, Sircar K. Spatial Transcriptomic Evaluation of Tumor and Tumor Microenvironment of Renal Cell Carcinoma With Respect to Regional Histology And Response To Immunotherapy. USCAP 113th Annual Meeting Bringing Education to Life 104(3):S940-42, 2024. e-Pub 2024.
6. Alkamachi B, Hwang M, Sircar K, Peshoff M, Tamboli P, Rao P. Best Practices for Grossing and Reporting of Post-immunotherapy Nephrectomy Specimens: A Single Institution Experience of 70 Cases. 112th USCAP Annual Meeting 103(3), 2023. e-Pub 2023.
7. Ebare K, Lee Y, Christian P, Noorbakhsh C, Tian XJ, Wang J, Kannan K, Bhat K, Karam JA, Sircar K. MAGE Family of Cancer Testis Antigen Genes are Associated with Resistance to Immune Checkpoint Inhibitors in Sarcomatoid Renal Cell Carcinomas 102(1):591-592, 2022. e-Pub 2022.
8. Nair V, Tian XJ, Noorbakhsh C, Lee Y, Hwang M, Wang, J, Wang ZX, Chen K, Karam JA, Kannan K, Bhat K, Sircar K. Single Region Sampling Does Not Capture the Intra-Tumoral Immune Heterogeneity of Sarcomatoid Renal Cell Carcinoma. Laboratory Investigation. Laboratory Investigation 102(Suppl 1):641-642, 2022. e-Pub 2022.
9. Hahn AW, Viscuse PV, Surasi DS, Bathala T, Wiele AJ, Starbuck MW, Campbell MT, Shah AY, Jonasch E, Gao JJ, Alhalabi O, Sircar K, Tannir NM, Msaouel, P. Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint thereapy (ICT): The MD Anderson Cancer experience. Journal of Clinical Oncology 40(6), 2022. e-Pub 2022.
10. Alhalabi O, Thouvenin J, Negrier S, Vano YA, Campedel L, Hasanov, E, Bakouny Z, Hahn AW, Bilen MA, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf G, Tannir NM. Immuno-oncology (IO)combination plus/- VEGF targeted therapy (VEGF TT) in patients (PTS) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study. Journal of Clinical Oncology 40(6), 2022. e-Pub 2022.
11. Guo T, Li J, Wani K, Murugan P, Brimo F, Lazar A, Tamboli P, Zhang J, Bhat K, Sircar K. Gene Methylation Patterns of Aggressive Chromophobe Renal Cell Carcinoma 34(2):559, 2021. e-Pub 2021.
12. Wilson N, Wiele AJ, Surasi DS, Rao P, Sircar K, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy of gemcitabine plus doxorubicin (Gem plus Dox) in patients with renal medullary carcinoma (RMC). Journal of Clinical Onocology 39(6), 2021. e-Pub 2021.
13. Wiele AJ, Surasi DS, Rao P, Sircar K, Bathala T, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. The efficacy of bevacizumab erlotinib (B plus E)in patients (pts) with renal medullary carcinoma (RMC). Journal of Clinical Oncology 39(6), 2021. e-Pub 2021.
14. Hwang, M, Kerns, BJ, Lee Y, Thompson D, Karam J, Rao P, Tamboli P, Bhat K, Sircar K. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era. Laboratory Investigation 100(1):928, 2020. e-Pub 2020.
15. Oramas D, Kim T, Chen K, Rao P, Tamboli P, Karam J, Shapiro D, Sircar K. Response to Immune Checkpoint Therapy and Clinical Outcome is Not Related to Proportion of Sarcomatous Component in Sarcomatoid Renal Cell Carcinoma 100(1):991, 2020. e-Pub 2020.
16. Msaouel P, Thall PF, Yuan Y, Wang XM, Jonasch E, Gao JJ, Campbell MT, Shah AY, Corn PG, a T, Ahrar K, Rao P, Sircar K, Der-Torossian H, Tannir NM. A phase I/II of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that profressed on prior VEGF-targeted therapy. Journal of Clinical Oncology 38(6), 2020. e-Pub 2020.
17. Hasanov E, Peterson CB, Matin SF, Wood CG, Sircar K, Tannir NM, Jonasch E. Hypoxia signaling and immune infiltration in a presurgical trial of sunitinib in patients with clear cell renal cell carcinoma (RCC). Journal of Clinical Onocology 37(15), 2019. e-Pub 2019.
18. Kojima Y, Shang M, Sircar K, Habra M. Potential therapeutic Biomarker profiles in Adrenocortical Carcinomas 99(1), 2019.
19. Tang S, Akgul M, Kim T, Chen K, Wang F, Sircar K. Manual Estimation of Tumor Purity is Poor Compared to Sequencing Based Estimates 99(1):1965, 2019.
20. Tang, S, Akgul, M, Kim, T, Chen, K, Wang, F, Sircar, K. Manual Estimation of Tumor Purity is Poor Compared to Sequencing Based Estimates. Laboratory Investigation 99(1):1965, 2019. e-Pub 2019.
21. Akgul, M, Kim, T, Qi, Y, Alouch, N, Murugan, P, Shen, S, Brim, F, Rao, P, Tamboli, P, Chen, K, Sircar, K. TP53 and PTEN Mutational Status and Outcome Prediction in Chromophobe Renal Cell Carcinoma. Laboratory Investigation 99(1):781, 2019. e-Pub 2019.
22. Akgul M, Kim T, Qi Y, Alouch N, Murugan P, Shen S, Brim F, Rao P, Tamboli P, Chen K, Sircar K. TP53 and PTEN Mutational Status and Outcome Prediction in Chromphobe Renal Cell Carcinoma 99(1):781, 2019.
23. Hruska C, Sircar K, Tamboli P, Rao P. Primary Neuroendocrine Tumors of the Kidney: A clinicopathologic analysis of 17 cases. Does the grading system matter?. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 98(1):350-350, 2018. e-Pub 2018.
24. Ruiz-Cordero R, Li L, Qi Y, Kawakami F, Alouch N, Lu W, Chen K, Brimo F, Wang, J Tamboli P, Rao P, Sircar K. Hybrid Oncocytic Renal Tumors Display A Molecular Profile Intermediate Between Oncocytoma And Chromophobe Renal Cell Carcinoma. Modern Pathology 31(3):380-380, 2018. e-Pub 2018.
25. Ma S, Alouch N, Hawkins M, Ruiz-Cordero R, Li L, Kawakami F, Brimo F, Wang J, Tamboli P, Sircar K, Rao P. Aggressive Chromophobe RCC (ChRCC) Molecularly and Immunochemically Separable From Indolent ChRCC. Modern Pathology 31(3):361-362, 2018. e-Pub 2018.
26. Kojima Y, Hruska C, Sircar K, Habra M Zhang M. Adrenal cortical carcinomas: A microsatellite instability-high tumor. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology 31(2):357-357, 2018. e-Pub 2018.
27. Ma SH, Alouch N, Hawkins M, Ruiz-Cordero R, Li LR, Kawakami F, Brimo F, Wang J, Tamboli P, Sircar K, Rao P. Aggressive Chromophobe RCC (ChRCC) Are Molecularly and Immunochemically Separable From Indolent ChRCC. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology 98(1), 2018. e-Pub 2018.
28. Ruiz-Cordero R, Li LR, Qi Y, Kawakami F, Alouch N, Lu W, Chen K, Brimo F, Wang J, Tamboli P, Rao P, Sircar K. Hybrid Oncocytic Renal Tumors Display A Molecular Profile Intermediate Between Oncocytoma and Chromophobe Renal Cell Carcinoma. 107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology 98(1):380-380, 2018. e-Pub 2018.
29. Ruiz-Cordero, Rao, P, Tamboli, P, Singh, R, Routbort, MJ, Sircar, K. Characterization of Driver Mutations in Hybrid Renal Oncocytic Tumors. Laboratory Investigation 97:253A, 2017. e-Pub 2017.
30. Kawakami F, Sircar K, Tamboli P, Rodriguez-Canales J, Wood CG, Karam JA. Immunohistochemical phenotype analysis of a large series of sarcomatoid renal cell carcinoma. Laboratory Investigation(97):235A, 2017. e-Pub 2017.
31. Sircar K, Wang, Z, Kim, T, Peng, B, Karam, JA, Creighton, CJ, Chow, C, Canales R, J, Tamboli, P, Mills, G, Shaw, K, Chen, K. Sarcomatoid Clear Cell RCC Shows a Distinct Molecular Pathogenesis and Driver Mutation Profile. Laboratory Investigation 96((S1)):262A, 2016. e-Pub 2016.
32. Kawakami F, Sircar K, Rodriguez-Canales J, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Expression of PD-1 and PD-L1 in patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). Journal of Clinical Oncology 34(2 SUPPL):1, 2016. e-Pub 2016.
33. Adibi, M, Thomas, AZ, Borregales, L, Merrill, MM, Sircar, K, Tamboli, P, Slack, R, Chen, HC, Tannir, NM, Jonasch, E, Matin, SF, Wood, CG, Karam, JA. Percentage of sarcomatoid component as a prognostic indicator for survival in sarcomatoid renal cell carcinoma. Journal of Clinical Oncology 33(7 Supplement S #499), 2015. e-Pub 2015.
34. Singh R, Tamboli P, Czerniak BA, Medeiros LJ, Luthra R, Sircar K. Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma Pose a Challenge for Personalized Cancer Therapy. Laboratory Investigation 95(Supplement 1 #134):259A-260A, 2015. e-Pub 2015.
35. Murugan, P, Yoo, S-Y, Majewski, T, Voicu, H, Tamboli, P, Baggerly, K, Czerniak, B, Aldape K, Sircar K. Rhabdoid RCC Is Molecularly Distinct from Fuhrman Grade 4 RCC. Laboratory Investigation 94(1):251A-251A, 2014. e-Pub 2014.
36. Sircar, K, Yoo, S-Y, Majewski, T, Patel, L, Voicu, H, Wani, K, Tamboli, P, Baggerly, K, Aldape, K, Czerniak, B. The Epithelioid and Sarcomatoid Components of Sarcomatoid RCC Are Molecularly Similar to Each Other but Distinct from Fuhrman Grade 4 Non-Sarcomatoid RCC. Laboratory Investigation 94(1):261A-261A, 2014. e-Pub 2014.
37. Atherton D, Sircar K, Tamboli P, Rao P. Renal Oncocytic Tumors with Hybrid Features Occurring in a Sporadic Setting: A Clinicopathologic Study of 22 Cases. Laboratory Investigation 93(1):196A-196A, 2013. e-Pub 2013.
38. Xu B, Abourbih S, Sircar K, Kassouf W, Aprikian A, Tanguay S, Brimo F. Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated with Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma. Modern Pathology 26(2):259A-260A, 2013. e-Pub 2013.
39. Xu B, Abourbih S, Sircar K, Kassouf W, Aprikian A, Tanguay S, Brimo F. Diagnostic and Prognostic Role of Immunohistochemical Expression of Napsin A in Renal Cell Carcinoma: A Study Including 233 Primary and Metastatic Cases. Modern Pathology 26(2):259A-259A, 2013. e-Pub 2013.
40. Sircar K, Majewski T, Yoo SY, Patel L, Wani K, Tamboli P, Czerniak B, Baggerly K, Aldape K. Sarcomatoid and Rhabdoid RCC Show a Similar, Poor Prognosis Molecular Signature That Is Separable from Non-Sarcomatoid RCC. Modern Pathology 26(2):249A-249A, 2013. e-Pub 2013.
41. Sircar K, Huang L, Hu Y, Dhillon J, Cogdell D, Aprikiam A, Navone N, Troncoso P, Zhang W. Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin as a Therapeutic Target in Castration-Resistant Prostate Cancer. Modern Pathology 25(Suppl 2 #1012):241A, 2012. e-Pub 2012.
42. Sircar K, Majewski T, Wani K, McDonald J, Baggerly K, Tamboli P, Czerniak B, Aldape K. Sarcomatoid Renal Cell Carcinoma Shows a Distinct Transcriptomic Profile That Is Not Associated with Epithelial to Mesenchymal Transition Markers. Modern Pathology 25(Suppl 2 #1013):241A-242A, 2012. e-Pub 2012.
43. Sircar K, Huang H, Cogdell D, Dhillion J, Tzelepi V, Navone N, Bismar T, Koumakpayi H, Saad F, Aprikian A, Troncoso P, Zhang W. Asparagine Synthetase Is a Target in Castration Resistant Prostate Cancer. United States & Canadian Academy of Pathology 100th Annual Meeting, 2011. e-Pub 2011.
44. Monzon FA, Alvarez K, Peterson L, Sircar K, Tamboli P, Jonasch E. Chromosomal Imbalances Identify Pathways Associated with Resistance to Antiangiogenic Therapy in Clear Cell Renal Cell Carcinoma. United States & Canadian Academy of Pathology 100th Annual Meeting, 2011. e-Pub 2011.
45. Squire JA, Ludkovski O, Evans A, Sircar K, Bismar T, Yoshimoto M. Detection of Genomic Deletions with Higher Sensitivity and Specificity in Formalin Fixed Paraffin Embedded Tissue Samples Using Fluorescence In Situ Hybridization. Journal of Molecular Diagnostics 12(6):910-911, 2010. e-Pub 2010.
46. Sircar K, Cogdell D, Dhillon J, Huang H, Hu L, Navone N, Katz R, Khanna A, Bismar TA, Koumakpayi IH, Saad F, Aprikian AG, Monzon FA, Troncoso P, Zhang W. Integrative Molecular Profiling of Castration Resistant Prostate Cancer. Modern Pathology 23(Suppl 1 #981):220A, 2010. e-Pub 2010.
47. Monzon FA, Alvarez K, Sircar K, Tamboli P, Jonasch E. Virtual Karyotyping with SNP Arrays Identifies Chromosomal Imbalances as Biomarkers for Tumor Progression in Clear Cell Renal Cell Carcinoma. Modern Pathology 23(Suppl 1 #925):208A, 2010. e-Pub 2010.
48. Bakkar A, Yoshimoto M, Liu S, Duan Q, Sircar K, Squire JA, Bismar TA. Characterization of ERG Rearrangements, PTEN and SPINK1 Expression in Hormone Refractory Prostate Cancer Associated with Lethal Disease. Modern Pathology 23(1 #782):177A-177A, 2010. e-Pub 2010.
49. Alshalalfa M, Bakkar A, Sircar K, Squire JA, Alhajj R, Bimar TA. Molecular Pathways Associated with ERG Rearranged PTEN Deleted Hormone Refractory Prostate Cancer. Modern Pathology 23(1):175A-175A, 2010. e-Pub 2010.
50. Monzon FA, Alvarez K, Sircar K, Tamboli P, Jonasch E. Virtual Karyotyping with SNP Arrays Identifies Chromosomal Imbalances as Biomarkers for Tumor Progression in Clear Cell Renal Cell Carcinoma. Modern Pathology 23(Suppl. 1 #925):208A-208A, 2010. e-Pub 2010.
51. Capitanio U, Karakiewicz PI, Margulis V, Raman JD, Lotan Y, Kassouf W, Ziqeuner RE, Roscigno M, Remzi M, Bolenz C, Langner C, Weizer AZ, Kikuchi E, Montorsi F, Bensalah K, Koppie TM, Fernandes MI, Wheat J, Wood CG, Isbarn H, Oya M, Ng CK, Sircar K, Shariat SF. Laparoscopic Nephroureterectomy Does Not Undermine Cancer Control Outcomes in Selected Patients With Non-Metastatic Upper Tract Urothelial Carcinoma. Journal of Urology 181(4):278-278, 2009. e-Pub 2009.
52. Rao P, Tamboli P, Tanguay S, Aldape KD, Sircar K. YKL-40 as a Marker of Epithelial to Mesenchymal Transitional in Primary and Metastatic RenalCell Carcinoma. Modern Pathology 22(Suppl 1 #862):190A, 2009. e-Pub 2009.
53. Sher K, Rao P, Chen G, Guoit MC, Fahmy MA, Tanguay S, Aldape K, Sircar K. Oncofetal (IMP3) and Stem Cell Markers in Primary and Metastatic Renal Cell Carcinoma. Modern Pathology 22(Suppl 1 #876):193A, 2009. e-Pub 2009.
54. Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Jiao J, Alaoui-Jamali MA, Bismar TA. Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer. Modern Pathology 22(Suppl 1 #742):165A-165A, 2009. e-Pub 2009.
55. Rao P, Tamboli P, Tanguay S, Aldape KD, Sircar K. YKL-40 as a Marker of Epithelial to Mesenchymal Transition in Primary and Metastatic Renal Cell Carcinoma. Modern Pathology 22(Suppl 1 #862):190A-190A, 2009. e-Pub 2009.
56. Chen YB, Moss B, Banerjee S, Perner S, Lagargue C, Rickman DS, Sircar K, Bismar TA, Rubin MA, Demichelis F. Molecular Pathways Associated with Hormone Refractory TMPRSS2-ERG Fusion Prostate Cancer. Modern Pathology 22(Suppl 1 #1674):369A-369A, 2009. e-Pub 2009.
57. Feifer A, Al-Otaibi MF, Sircar K, Begin LR, Aprikian AG, Kassouf W, Tanguay S. Pathologic disease progression on repeat transrectal biopsy in a contemporary watchful waiting prostate cancer cohort. Journal of Urology 179(4):195-196, 2008. e-Pub 2008.
58. Abou Youssif TM, Tanguay S, Alam-Fahmy M, Koumakpayi IH, Sircar K. Expression of PI3K/AKT/mTOR pathway in renal cell carcinoma metastases: Correlation with pathologic findings and survival. Journal of Urology 179(4):210-210, 2008. e-Pub 2008.
59. Fahmy MA, Al-Marozooqi A, Koumakpayi IH, Chen G, Aboyouef T, Tanguay S, Sircar K. Activation status of the PI3K/AKT/mTOR pathway in metastatic renal cell carcinomas and their matched primary tumors. Modern Pathology 21(Suppl 1 #706):155A, 2008. e-Pub 2008.
60. Sircar K, Yoshimoto M, Koumakpayi IH, Chen G, Darnell A, Aprikian AG, Saad F, Bismar TA, Squire JA. PTEN gene dosage affects downstream AKT pathway in hormone refractory prostate cancer. Modern Pathology 21(Suppl 1 #832):182A, 2008. e-Pub 2008.
61. Sircar K, Blumenkrantz M, Zlobec I, Chen G, Fahmy M, Aprikian A, Guiot MC. Multiple anti-cancer target expression in hormone refractory prostate cancer. Modern Pathology 20(Suppl 2, #801):176A, 2007. e-Pub 2007.
62. Sircar K, Bernard N, Cuello AC, Saragovi HU, Gold P, Aprikian AG, Moffett S. Novel Anti-PSMA monoclonal antibodies show superior tissue specificity. Modern Pathology 20(Suppl 2, #800):176A, 2007. e-Pub 2007.
63. Huwait HF, Yilmaz A, Sircar K, Trpkov K, Brimo F, Alrefae M, Cheng T, Begin L, Bismar TA. Testicular lymphoma: a clinico-pathologic study of 25 cases. Modern Pathology 19(Suppl 1, #691):153A, 2006. e-Pub 2006.
64. Sircar K, Gottlieb B, Aprikian A, Beitel L, Trifiro M, Alvarado C. Genetic heterogeneity of androgen sensitive and androgen independent prostate cancer: an analysis of androgen receptor CAG repeat lengths in germline, somatic and hermone refractory prostate cancer tissues. Modern Pathology 19(Suppl 1, #748):162A, 2006. e-Pub 2006.
65. Sircar K, Gaboury L, Scarlatta E, Mecteau M, Aprikian A, Tanguay S, Fahmy N, Lanoix J. Mirror image tissue banking of radical prostatectomy specimens enables isolation of epithelial plasma membranes for proteomics while preserving pathologic quality of retrieved tissues. Modern Pathology 19(Suppl 1, #747):162a, 2006. e-Pub 2006.
66. Gottlieb B, Alvarado C, Beitel LK, Sircar K, Aprikian A, Trifiro M. Single locus gene mutations and prostate cancer. Can mutations in the androgen receptor gene be directly linked to the occurrence of prostate cancer?. American Society of Human Genetcs 55th Meeting. Salt Lake City, UT, 2005. e-Pub 2005.
67. Gottlieb B, Alvarado C, Bietel LK, Sircar K, Aprikian A, Trifiro M. A tumor specific examination into the significance of androgen receptor gene alteration with functional consequences in prostate cancer. Endcrine Society's 87th Annual Meeting. San Diego, CA(#P2-665), 2005. e-Pub 2005.
68. Chen J, Gokden N, Greene G, Kadlubar FF, Sircar K, Aprikian A, Chen JZ. Implications of mitochondrial DNA modifications in prostate malignancy. The 4th Annual CPC-BioNet Meeting. Vancouver, BC, 2005. e-Pub 2005.
69. Omeroglu A, Alam M, Tanguay S, Aprikian A, Sircar K. Comparative study of immunohistochemical profiles of fetal and adult nephrons using renal tumor markers. Modern Pathology 18(Suppl 1):157A, 2005. e-Pub 2005.
70. Sircar K, Alam-Fahmy M, Aprikian A, Beitel L, Gottleib B, Trifiro M, Alvarado C. Androgen receptor CAG tract hetertogeneity in benign and malignant prostatic glands. Modern Pathology 18(Suppl 1):164A, 2005. e-Pub 2005.
71. Alvarado C, Beitel LK, Sircar K, Aprikian A, Gottlieb B, Trifiro M. Novel somatic changes of the human androgen receptor CAG tract in microdissected specimens from prostate cancer. 12th International Congress of Endocrinology. Lisbon, Porgugal(#P1034), 2004. e-Pub 2004.
72. Chen G, Shukeir N, Potti A, Sircar K, Goltzman D, Rabbani SA. The Wnt-Beta-catenin pathway is expressed n prostate cancer and in bone metastases. J Bone Miner Res 18(Suppl 2), 2003. e-Pub 2003.
73. Sircar K, Ohori M, Scardino PT, Reuter VE. Negative repeat biopsy of prostate cancer patients predicts for low volume, low stage disease. Lab Invest 82(1):758, 2002. e-Pub 2002.
74. Sircar K, Tickoo SK, Bosl G, Reuter VE. Seminomatious and nonseminomatious differentiaion of mixed germ cell tumours of the testis: an immunohistochemical study of 24 cases. Lab Invest 82(1):757, 2002. e-Pub 2002.
75. Khan AL, Dodson A, Hewlett BR, Sircar K, Huizinga JD, Riddell RH, Campbell F. Immunohistochemical Investigation of the Role of Interstitial Cells of Cajal in Diverticular Disease. 179th Meeting of the Pathological Society of Great Britain and Ireland. Dundee, Scotland, 1999. e-Pub 1999.
76. Salama S, Sircar K, Hewlett R. Kit expression in melanocytic lesions: an analysis of conventional nevi, spitz and reed's nevi and melanoma. Am J Dermatopath 21(6):595, 1999. e-Pub 1999.
77. Sircar K, Hewlett BR, Chorneyko K, Riddell RH. Differentiation of diminuitive and partially myoid gut stromal tumors. Lab Invest 79:84A, 1999. e-Pub 1999.
78. Sircar K, Hewlett B, Riddell RH. Most gastrointestinal stromal tumors (GIST) arise from the interstitial cells of Cajal (ICC). Mod Pathol 11:71A, 1998. e-Pub 1998.

Book Chapters

1. Rao, P, Perrino, CM, Zynger, DL, Jorda, M, Tamboli, P, Sanchez, DF, Cubilla, AL, Iczkowski, KA, Zhang, M, Sircar, K. Genitourinary pathology (including adrenal gland). In: Oncologic Surgical Pathology. 1st. Springer, 1523-1726, 2020.
2. Sircar K, Tamboli P. Renal Mass Biopsy. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1st. Springer, 2020.
3. Guo CC, Zhang M, Sircar K. Tumors of the Renal Pelvis. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1st. Springer, 2020.
4. Tamboli P, Sircar K. Renal Cell Carcinoma, Pathologic Considerations. In: Renal Cell Cancer: Principles and Practice. 2nd. Springer, 2015.
5. Tamboli, P, Sircar, K. Renal Cell Carcinoma, Pathologic Considerations. In: Renal Cell Cancer: Principles and Practice. 1st. Springer, 17-28, 2011.

Letters to the Editor

1. Huizinga, JD, Berezin, I, Chorneyko, K, Thuneberg, L, Sircar, K, Hewlett, BR, Riddell, R, Kindblom, LG, Meis, JM, Kindblom, LG, Meis- Kindblom, JM. Interstitial cells of Cajal. American Journal of Pathology 153: 2008-2011, 1998.